Litcius/Paper detail

Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial

Silvio E. Inzucchi, Brian Claggett, Muthiah Vaduganathan, Akshay S. Desai, Pardeep S. Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Mikhail Kosiborod, Carolyn S.P. Lam, Felipe A. Martínez, Sanjiv J. Shah, Subodh Verma, Yaling Han, José Francisco Kerr Saraiva, Olof Bengtsson, Magnus Petersson, Anna Maria Langkilde, John J.V. McMurray, Scott D. Solomon

2022The Lancet Diabetes & Endocrinology41 citationsDOI

Topics & Concepts

MedicineHeart failureEjection fractionDapagliflozinInternal medicineAtrial fibrillationPlaceboCardiologyPrediabetesType 2 diabetesAdverse effectDiabetes mellitusEndocrinologyAlternative medicinePathologyDiabetes Treatment and ManagementHyperglycemia and glycemic control in critically ill and hospitalized patientsCardiovascular Function and Risk Factors
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial | Litcius